Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/1996
06/12/1996EP0715523A1 Purine nucleoside phosphorylase gene therapy for human malignancy
06/12/1996EP0423201B1 Mhc-mediated conjugates useful in ameliorating autoimmunity
06/12/1996CN1124457A Improved pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug
06/12/1996CN1124454A Rectal compositions
06/12/1996CN1124451A Liquid antacid compositions
06/12/1996CN1124449A Low-viscosity cosmetic and pharmaceutical emulsions
06/12/1996CN1124143A Powder preparation for healing damaged skin
06/12/1996CN1124140A Pharmaceutical compositions permitting the prolonged release of trimetazidine after oral administration
06/12/1996CN1124135A Producing method for vascular embolism porcelain powder
06/11/1996US5525631 Compositions of the ethyl ester of L-DOPA
06/11/1996US5525596 (r-(r*,r*))-3-((2-hydroxypropyl)amino)-3-methyl-n-2,3,4,5-tet rahydro-2-oxo-1-((2'-(h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)me thyl-1h-1-benzazepin-3-yl)butanamide, palmitoyl carnitine and cyclodextrin
06/11/1996US5525472 Mixing neutralized fatty acids, triglycerides or monoglycerides into escherichia cultures, then cell lysis in presence of magnesium ions and treatment of insoluble recovered material with nonionic detergents
06/11/1996US5525359 Microcapsules having a combined atelocollagen/polyholoside wall coagulated by a divalent cation and method for manufacturing these microcapsules and cosmetic or pharmaceutical or food compositions containing them
06/11/1996US5525358 Addition of polybutylene increases film flexibility
06/11/1996US5525357 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
06/11/1996US5525356 Amphoteric N-substituted acrylamide hydrogel and method
06/11/1996US5525354 Salts of dichloromethylene bisphosphonic acid in drug delivery form with acid-dissolving enteric coating, for oral administration
06/11/1996US5525338 Detection and therapy of lesions with biotin/avidin conjugates
06/11/1996US5525337 Detecting tumor cells by removing tissue or fluid sample, reacting with antibody capable of binding to surface antigen, detecting presence of antibody-antigen complex
06/11/1996CA2164777A1 Pharmaceutical, orally applicable composition
06/11/1996CA2054664C Hydrolytic stabilizer for unstable organic ions
06/06/1996WO1996017252A1 Stabilized aqueous steroid immunoassay standards
06/06/1996WO1996017063A1 Plasmids suitable for il-2 expression
06/06/1996WO1996017054A1 Method and compositions for reducing cholesterol absorption
06/06/1996WO1996016983A1 Cooperative combinations of ligands contained within a matrix
06/06/1996WO1996016680A1 Phosphocholine drug derivatives
06/06/1996WO1996016671A1 New antithrombotic formulation, process for its manufacturing, and use thereof
06/06/1996WO1996016661A2 Use of prostaglandin e1, e2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
06/06/1996WO1996016659A1 Cyclodextrins as suspending agents for pharmaceutical suspensions
06/06/1996WO1996016658A1 Indolocarbazole derivative preparation
06/06/1996WO1996016655A1 Novel enediyne quinone imines and methods of preparation and use thereof
06/06/1996WO1996016642A1 Matrix type patch preparation
06/06/1996WO1996016639A1 Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
06/06/1996WO1996016638A1 Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
06/06/1996WO1996016541A1 Polymer linked biological agents
06/06/1996CA2206526A1 Method and compositions for reducing cholesterol absorption
06/06/1996CA2206459A1 New antithrombotic formulation, process for its manufacturing, and use thereof
06/06/1996CA2206348A1 Cyclodextrins as suspending agents for pharmaceutical suspensions
06/06/1996CA2206303A1 Matrix type patch formulation
06/06/1996CA2206175A1 Cooperative combinations of ligands contained within a matrix
06/06/1996CA2205351A1 Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
06/06/1996CA2204902A1 Phosphocholine drug derivatives
06/05/1996EP0714912A2 GMP-140 derived lektin-like domain peptides and their ligands
06/05/1996EP0714903A1 New carbohydrate conjugates as cell adhesion inhibitors
06/05/1996EP0714656A1 Capsule shell compositions and their use
06/05/1996EP0714418A1 Cosmetic melanins
06/05/1996EP0714415A1 Aqueous copolymer dispersions
06/05/1996EP0714411A1 Bioadhesive starches and process for their preparation
06/05/1996EP0714407A1 Composition and methods using nitroxides to avoid oxygen toxicity
06/05/1996EP0714402A1 Polymer modification
06/05/1996EP0714386A1 Water-soluble nimesulide salt, and uses thereof for the treatment of inflammations
06/05/1996EP0714290A1 Compositions and methods for the detection and treatment of protein trafficking disorders and increasing secretory protein production
06/05/1996EP0714283A1 Personal cleansing compositions
06/05/1996EP0553121B1 Aqueous emulsion and aerosol delivery system using same
06/05/1996EP0397652B1 Water insoluble derivatives of hyaluronic acid
06/05/1996DE19501022C1 Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung Transdermal therapeutic system for administration of (S) -3-methyl-5- (1-methyl-2-pyrrolidenyl) isoxazole or a pharmaceutically acceptable salt thereof and process for its preparation
06/05/1996CN1124014A Solubilizing agent and external preparation containing the same
06/05/1996CN1124006A Cholesterol lowering drink mix compositions
06/05/1996CN1123793A Non-reducing oligosaccharide and its production and use
06/05/1996CN1123665A Long-effect and broad-spectrum antibiotic granules and its production
06/04/1996US5523492 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
06/04/1996US5523402 Tripyridyl macrocyclic compounds
06/04/1996US5523232 Use of restriction endonucleases against viruses, including HIV
06/04/1996US5523099 Stability, reduced sweetness, appropriate viscosity, non-crystallizing and less fermentabiity; foods, beverages, cosmetics and drugs
06/04/1996US5523094 Aqueous mixture of alfuzosin, organic solvent and absorption promoter
06/04/1996US5523091 Containing silicone, gelling agent, emulsifier
06/04/1996CA2019863C Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
05/1996
05/30/1996WO1996016179A1 Enzyme gene therapy catalysing prodrug extracellular conversion
05/30/1996WO1996015826A1 Composition and method for enhancing electrotransport agent delivery
05/30/1996WO1996015816A2 Stable n-terminally linked dtpa:protein compositions and methods
05/30/1996WO1996015815A1 Microcapsules, method of making and their use
05/30/1996WO1996015814A1 Preparation of hollow microcapsules
05/30/1996WO1996015811A1 Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
05/30/1996WO1996015810A1 Monofunctional and/or polyfunctional polylysine conjugates
05/30/1996WO1996015809A2 Process for the preparation of a pharmacologically active chemical combination
05/30/1996WO1996015797A1 Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
05/30/1996WO1996015793A1 Percutaneously absorbable preparation
05/30/1996WO1996015790A1 Lubeluzole intravenous solutions
05/30/1996WO1996015786A2 Oral compositions containing ondansetron
05/30/1996WO1996015778A1 Polynucleotide compositions
05/30/1996WO1996015773A1 Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds
05/30/1996DE19541284A1 Verfahren zur Immunmodulation Methods for immunomodulation
05/30/1996CA2205606A1 Lubeluzole intravenous solutions
05/30/1996CA2205593A1 Enzyme gene therapy catalysing prodrug extracellular conversion
05/30/1996CA2205486A1 Polynucleotide compositions
05/30/1996CA2181364A1 Preparation for percutaneous absorption
05/29/1996EP0713697A1 Analgesic anti-inflammatory adhesive preparations
05/29/1996EP0713696A1 Topical application product containing a lipase and a precursor of hydroxyacid
05/29/1996EP0713652A1 Calcium fortified beverages
05/29/1996EP0713496A1 Fibrin-targeted inhibitors of thrombin
05/29/1996EP0713399A1 Method for binding to polymers
05/29/1996EP0713395A1 Polymeric carriers for non-covalent drug conjugation
05/29/1996EP0713390A1 Gelatin capsules containing a highly concentrated acetaminophen solution
05/29/1996EP0713389A1 Hydrolyzed gelatin as a flavor enhancer in a chewable tablet
05/29/1996EP0575481B1 Novel liquid compositions based on derivatives of 1,4 substituted piperidine
05/29/1996EP0477315B1 Inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine or salts formed with cyclodextrin derivatives, preparation thereof and pharmaceutical compositions containing the same
05/29/1996EP0469065B1 Recombinant antibody-toxin fusion protein
05/29/1996EP0311632B1 Surface active lactams
05/29/1996CN1123525A Tylosin containing sustained release veterinary compositions
05/29/1996CN1123524A Compositions in the form of solid solutions
1 ... 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 ... 1712